The 18 most recent market catalysts affecting $THC, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 3, 2026
Corporate Catalyst
Bullish
Impact 65
Wells Fargo Maintains Overweight on Tenet Healthcare, Raises Price Target to $281
Wells Fargo analyst Stephen Baxter has maintained an 'Overweight' rating on Tenet Healthcare (THC) and significantly raised the price target from $231 to $281. This upgrade signals…
Jul 28, 2026
Corporate Catalyst
Bullish
Impact 75
Tenet Healthcare shares are trading higher after multiple analyst firms raised their respective price targets on the stock.
This headline signals a strong positive sentiment for Tenet Healthcare (THC), driven by professional analyst upgrades. Such revisions often lead to increased investor confidence an…
Jul 28, 2026
Corporate Catalyst
Bullish
Impact 55
Truist Securities Maintains Buy on Tenet Healthcare, Raises Price Target to $290
Truist Securities analyst David Macdonald has maintained a 'Buy' rating on Tenet Healthcare (THC) and raised the price target from $270 to $290. This action indicates a continued b…
Jul 28, 2026
Corporate Catalyst
Bullish
Impact 65
Guggenheim Maintains Buy on Tenet Healthcare, Raises Price Target to $283
Guggenheim analyst Jason Cassorla maintained a 'Buy' rating on Tenet Healthcare (THC) and raised the price target from $242 to $283. This action indicates a strengthened positive o…
Jul 27, 2026
Corporate Catalyst
Bullish
Impact 55
UBS Maintains Buy on Tenet Healthcare, Raises Price Target to $308
UBS analyst A.J. Rice has maintained a 'Buy' rating on Tenet Healthcare and raised the price target from $288 to $308. This action signals continued confidence from a major investm…
Jul 27, 2026
Corporate Catalyst
Bullish
Impact 55
TD Cowen Maintains Buy on Tenet Healthcare, Raises Price Target to $263
TD Cowen analyst Ryan Langston maintained a 'Buy' rating on Tenet Healthcare (THC) and raised the price target from $233 to $263. This action signals a continued bullish outlook fr…
Jul 27, 2026
Corporate Catalyst
Bullish
Impact 55
Morgan Stanley Maintains Overweight on Tenet Healthcare, Raises Price Target to $274
Morgan Stanley's analyst Craig Hettenbach has raised the price target for Tenet Healthcare (THC) from $254 to $274 while maintaining an 'Overweight' rating. This action signals inc…
Jul 27, 2026
Corporate Catalyst
Bullish
Impact 75
Tenet Healthcare shares are trading higher after RBC Capital maintained an Outperform rating on the stock and raised its price target from $236 to $283.
This headline represents a significant corporate catalyst for Tenet Healthcare. An 'Outperform' rating maintained, coupled with a substantial price target increase, signals strong …
Jul 27, 2026
Corporate Catalyst
Bullish
Impact 55
RBC Capital Maintains Outperform on Tenet Healthcare, Raises Price Target to $283
RBC Capital's analyst Ben Hendrix maintained an 'Outperform' rating on Tenet Healthcare (THC) and significantly raised the price target from $236 to $283. This action signals stron…
Jul 24, 2026
Corporate Catalyst
Bullish
Impact 95
Tenet's Blockbuster Quarter Sends Stock Flying, 2026 Outlook Gets Major Upgrade
Tenet Healthcare (THC) delivered a blockbuster second quarter in 2026, significantly exceeding Wall Street's earnings and revenue estimates. This strong performance was attributed …
Jul 24, 2026
Market Technicals
Bullish
Impact 65
12 Health Care Stocks Moving In Friday's Intraday Session
This filing details intraday stock performance for 12 healthcare companies, categorizing them as gainers or losers. The primary driver for Tenet Healthcare's significant gain was i…
Jul 24, 2026
Corporate Catalyst
Bullish
Impact 65
Barclays Maintains Overweight on Tenet Healthcare, Raises Price Target to $271
Barclays analyst Andrew Mok maintained an 'Overweight' rating on Tenet Healthcare (THC) and raised the price target from $240 to $271. This action signals continued confidence from…
Jul 24, 2026
Corporate Catalyst
Bullish
Impact 85
Tenet Healthcare shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 guidance.
Tenet Healthcare's better-than-expected Q2 results and raised FY26 guidance are a strong positive catalyst, indicating effective management and a healthy demand environment for the…
Jul 23, 2026
Corporate Catalyst
Bullish
Impact 85
Tenet Healthcare shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 guidance.
This headline indicates a strong corporate catalyst for Tenet Healthcare (THC), with better-than-expected Q2 results and an upward revision to its long-term financial guidance. Thi…
Jul 23, 2026
Corporate Catalyst
Bullish
Impact 85
Tenet Healthcare Raises FY2026 Adj EPS Guidance from $16.38-$18.68 to $20.30-$21.69 vs $17.88 Est; Raises FY2026 Sales Guidance from $21.500B-$22.300B to $21.900B-$22.500B vs $21.996B Est
Tenet Healthcare (THC) has issued an 8-K filing announcing a substantial increase in its FY2026 adjusted EPS and sales guidance. The new EPS range of $20.30-$21.69 is significantly…
Jul 23, 2026
Corporate Catalyst
Bullish
Impact 95
Tenet Healthcare Q2 Adj. EPS $6.12 Beats $4.23 Estimate, Sales $5.628B Beat $5.430B Estimate
Tenet Healthcare's Q2 earnings report shows a substantial beat on both adjusted EPS and sales estimates. The adjusted EPS of $6.12 significantly surpassed the $4.23 consensus, repr…
Jul 14, 2026
Corporate Catalyst
Bearish
Impact 75
Tenet Healthcare shares are trading lower amid sympathy with HCA Healthcare after that company lowered its FY26 GAAP EPS guidance.
HCA Healthcare's lowered FY26 GAAP EPS guidance is a significant negative catalyst, not just for HCA but for the entire healthcare provider sector. The 'sympathy' sell-off in Tenet…
Jul 13, 2026
Corporate Catalyst
Bullish
Impact 55
Wells Fargo Maintains Overweight on Tenet Healthcare, Raises Price Target to $231
Wells Fargo's analyst Stephen Baxter has maintained an 'Overweight' rating on Tenet Healthcare (THC) and raised the price target from $213 to $231. This action signals continued co…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.